

where said mammal is not immunized with an immunogen in such amounts and at such times as would substantially induce [said immune-mediated disorder] diabetes mellitis.

REMARKS

1. The only substantive rejection in this case is against claims 2-18, 21-35 and 37, for insufficient enablement. However, the Examiner concedes that the disclosure is enabling for "a method [of immunizing] mammals which decreases the incidence of diabetes mellitis". In the interest of speedy resolution, Applicants have amended claims 3, 21, 23-27, 30, 33, 35 and 37 so that all pending claims are limited to the admittedly enabled indication. This is without prejudice or disclaimer to pursuing the subject matter in a continuing application.

2. Certain of the claims were also rejected for indefiniteness.

2.1 Claim 3 has been rewritten in independent form, hence, claims 2-18 are no longer dependent on cancelled claim 1.

2.2 Claim 9 has been amended to refer to claim 3.

2.3 The Examiner states that she is uncertain of what was intended by claim 32. However, the quoted language is from original claim 31, not 32, and does not reflect the correction of "proceeding" to --preceding-- in the last amendment.

An example of an immunization schedule within claim 31 is the following:

<u>Dose</u>	<u>Age</u>	
1	7 days	[see claim 30 (a)]
2	14 days	[see claim 30 (b)]
3	21 days	[ditto]
4	42 days	[see claim 31 and preamble of claim 30]

Dose 1 is given prior to the age of 8 days, and doses 2 and 3 between the ages of 11 and 26 days. The last dose at an age preceding 26 days of age was dose 3 at 21 days of age. Dose 4 was administered 21 days later, which is within the claimed interval of "at least 11 days, but less than 26 days".


Claim 32 would cover an administration schedule in which to the above schedule one added a dose 5 at age 63 days. This would be 21 days (i.e., between 11 and 26 days) after the "further administration" recited in claim 30.

To clarify these claims, we have inserted an identifying --(c)--, before the "additionally administering" at the beginning of the second line of claim 31, and an identifying --(d)-- before "administering" at the beginning of the second line of claim 32. In addition, at the end of claim 32, after "administration", we have added --of step (c)--.

It is respectfully concluded that the claims are now in
condition for allowance.

Respectfully submitted,

BROWDY AND NEIMARK
Attorneys for Applicant

By: 
Iver P. Cooper
Reg. No. 28,005

419 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
IPC:lms

f:\user19\wpla-clclasi.amd